Mirdametinib

Mirdametinib

• CAS Number: 391210-10-9
• UNSPSC Description: Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts[1][2][3].
• Target Antigen: Apoptosis; Autophagy; MEK
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;MAPK/ERK Pathway
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/PD0325901.html
• Purity: 99.95
• Solubility: DMSO : ≥ 56 mg/mL
• Smiles: O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO
• Molecular Weight: 482.19
• References & Citations: [1]Barrett SD, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4.|[2]Henderson YC, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76.|[3]Judith S. Sebolt-Leopold, et al. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Phase 2